Invitae Stock Jumps As Higher Test Volume More Than Doubles Q2 Topline, Raises FY21 Sales Outlook

Loading...
Loading...
  • Invitae Corporation NVTA, after the close of the market on Tuesday, reported its second-quarter revenues of $116.3 million, +152% Y/Y, exceeding the consensus Wall Street estimate of $108.3 million.
  • Revenues from testing totaled $111.5 million, a sharp increase from $45.1 million in Q2 2020. Other revenues more than quadrupled during the quarter to $4.8 million from $1.1 million in the prior year.
  • Invitae's strong financial performance during the quarter was driven by a 154% increase in billable test volume to 287,000 billed tests compared to 113,000 tests during the year-ago period. 
  • The international market represented 19% of total billable test volume, Roxi Wen, Invitae's new CFO, said on a call to discuss the company's financial results.
  • The preliminary average cost per billable unit was $317, down from $380 a year ago. Non-GAAP average cost per unit was $261 in the quarter.
  • Its R&D expenses were $116.9 million, up 56%, while SG&A expenses were $114 million, a 74% increase.
  • Invitae's net loss came in at $(0.85) per share, down from $(0.97) in Q2 2020, but missing the analysts estimate of $(0.65).
  • Invitae ended the quarter with $1.11 billion in cash and cash equivalents and $422.5 million in marketable securities.
  • FY21 Guidance: Invitae increased its revenue outlook to $475 million - $500 million (consensus $463 million), against $450 million previously expected.
  • Price Action: NVTA shares are up 10.7% at $31.68 during the market session on the last check Wednesday.
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLong IdeasNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...